Feb 18, 2015 4:21 pm EST Atara Biotherapeutics Announces Closing of Underwritten Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares
Nov 06, 2014 9:05 am EST Atara Biotherapeutics' Collaborating Investigators to Present Data at the American Society of Hematology Annual Meeting 2014
Oct 22, 2014 6:50 am EDT Atara Biotherapeutics Doses First Patient in Phase 1 Clinical Study of STM 434, an Activin Inhibitor
Sep 23, 2014 9:00 am EDT Atara Biotherapeutics Announces Immunotherapy Alliance With Memorial Sloan Kettering Cancer Center